Why Nebius Stock Soared Again in October

Key Points Nebius has the assets to accomodate AI innovators just as demand is soaring. Management has backed up bold growth predictions with a big ...

Read more

3 Reasons Amazon Is a No-Brainer Buy Right Now

Key Points Amazon’s advertising business is its fastest-growing segment. AWS is gaining traction in the AI space. Amazon’s gross margins have improved dramatically over the ...

Read more

Amgen Stock Momentum Builds as Institutions Return to Buying Mode

just delivered a strong beat-and-raise quarter. That’s pushed the stock to within striking distance of its 52-week high. That also puts it within striking distance ...

Read more

Crypto Market Recap: Bitcoin Dips, Ripple Unveils Brokerage Service for Digital Assets

Here’s a quick recap of the crypto landscape for Monday (November 3) as of 9:00 p.m. UTC. Get the latest insights on Bitcoin, Ether and ...

Read more

Ferrari Stock Looks Expensive — or Does It?

Key Points Ferrari (NYSE: RACE) is one of those companies investors can’t easily classify. It’s technically a carmaker, but its financials look more like a ...

Read more

Cadrenal Therapeutics, Inc. | Nasdaq

Valuation Based on our probability adjusted DCF model that takes into account potential future revenues for tecarfarin in LVADs, ESKD+AFib, and mechanical heart valves, CVKD ...

Read more

Billionaire David Tepper Has 15% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks

Key Points David Tepper is known for contrarian, deep-value bets and investing in distressed debt and equity. Alibaba stock has doubled since his hedge fund ...

Read more

HIT | Nasdaq

Title Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the ...

Read more

Why the Government Shutdown will End in November

Earlier this week, I wrote about how, though the 2025 bull market remains intact, cracks began to appear in the market internals, particularly in breadth ...

Read more

Cadrenal Therapeutics, Inc. | Nasdaq

Valuation Based on our probability adjusted DCF model that takes into account potential future revenues for tecarfarin in LVADs, ESKD+AFib, and mechanical heart valves, CVKD ...

Read more